A Study of Eltrekibart (LY3041658) in Healthy Participants

Exclusion Criteria

• •Have multiple severe allergies to prescription or nonprescription drugs
• •Are immunocompromised
• •Have had any of the following types of infection within 3 months prior to the screening visit:
• •* Serious, that is, requiring hospitalization, or intravenous or equivalent oral antibiotic treatment
• •* Opportunistic infections Note: Herpes zoster is considered active and ongoing until all vesicles are dry and crusted over
• •* Chronic, that is, duration of symptoms, signs, or treatment of 6 weeks or longer, or
• •* Recurring, including, but not limited to:
• •* herpes simplex,
• •* herpes zoster,
• •* recurring cellulitis, or
• •* chronic osteomyelitis.
• •Are currently pregnant or are intending to become pregnant or to breastfeed at any time in the study or within 16 weeks after receiving the single dose of study intervention.